Technology area
Vaccine
891 funded awards, $589.7M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 381 | $463,597 |
| CA (NCI) | National Cancer Institute | 206 | $745,612 |
| GM (NIGMS) | National Institute of General Medical Sciences | 83 | $612,291 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 43 | $929,940 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 29 | $666,640 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 29 | $635,475 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 28 | $349,954 |
| AG (NIA) | National Institute on Aging | 23 | $500,000 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 11 | $296,256 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 11 | $485,502 |
| EY (NEI) | National Eye Institute | 9 | $300,016 |
| HG (NHGRI) | National Human Genome Research Institute | 7 | $983,775 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 7 | $295,734 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 5 | $306,391 |
| DA (NIDA) | National Institute on Drug Abuse | 5 | $399,230 |
| MH (NIMH) | National Institute of Mental Health | 5 | $300,083 |
| OD | NIH Office of the Director | 3 | $999,973 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 2 | $691,428 |
| DC (NIDCD) | National Institute on Deafness and Other Communication Disorders | 2 | $968,800 |
| NR (NINR) | National Institute of Nursing Research | 1 | $378,893 |
| AT (NCCIH) | National Center for Complementary and Integrative Health | 1 | $335,257 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-22-176 | unknown | 247 |
| PA-23-230 | unknown | 136 |
| PA-21-259 | unknown | 116 |
| PA-24-245 | unknown | 63 |
| PA-22-178 | unknown | 50 |
| PA-23-232 | unknown | 37 |
| PA-20-260 | unknown | 34 |
| PA-24-247 | unknown | 29 |
| PA-21-262 | unknown | 28 |
| PA-20-265 | unknown | 20 |
| PA-19-272 | unknown | 18 |
| PA-22-177 | unknown | 10 |
| PA-24-246 | unknown | 9 |
| PA-20-047 | unknown | 8 |
| PA-20-272 | unknown | 8 |
| PA-23-231 | unknown | 6 |
| RFA-CA-21-001 | unknown | 5 |
| PAS-22-197 | unknown | 5 |
| PA-21-260 | unknown | 5 |
| PAR-22-073 | unknown | 5 |
| PAS-22-196 | unknown | 4 |
| PA-18-574 | unknown | 4 |
| PA-20-262 | unknown | 3 |
| PAS-19-317 | unknown | 3 |
| RFA-CA-20-033 | unknown | 2 |
| PA-23-233 | unknown | 2 |
| RFA-CA-23-034 | unknown | 2 |
| PA-24-248 | unknown | 2 |
| PA-22-179 | unknown | 2 |
| PAR-21-266 | unknown | 2 |
| RFA-NS-20-009 | unknown | 2 |
| PA-21-345 | unknown | 2 |
| RFA-DK-21-021 | unknown | 2 |
| RFA-DK-21-012 | unknown | 2 |
| RFA-HL-23-008 | unknown | 1 |
| RFA-CA-24-023 | unknown | 1 |
| PAR-24-131 | expired | 1 |
| PA-25-212 | unknown | 1 |
| RFA-DA-25-050 | unknown | 1 |
| PAR-23-311 | expired | 1 |
| PA-24-254 | unknown | 1 |
| RFA-DA-23-021 | unknown | 1 |
| PA-19-273 | unknown | 1 |
| RFA-NS-20-011 | unknown | 1 |
| RFA-HL-19-017 | unknown | 1 |
| PAR-21-247 | unknown | 1 |
| PAR-20-098 | unknown | 1 |
| PA-19-270 | unknown | 1 |
| PAS-19-316 | unknown | 1 |
| PAR-18-801 | unknown | 1 |
| PA-21-261 | unknown | 1 |
| RFA-ES-22-006 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10813104 | 2025 | CA | Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | SONALASENSE INC | $796,215 |
| 10850989 | 2025 | CA | CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | ROCK IMMUNE, INC. | $248,336 |
| 10918037 | 2025 | CA | Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | QUADRIGA BIOSCIENCES, INC. | $1,307,447 |
| 10932102 | 2025 | NS | Next-generation nanomedicine for acute ischemic stroke | NANOMUSE, LLC | $351,461 |
| 10997344 | 2025 | AI | A Vaccine for Lymphatic Filariasis, LFGuard™ | PAI LIFE SCIENCES, INC. | $452,996 |
| 10997404 | 2025 | AI | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | VERSATOPE THERAPEUTICS, INC. | $999,993 |
| 11003734 | 2025 | AI | Chikungunya Recombinant Subunit Vaccine | HAWAII BIOTECH, INC. | $998,229 |
| 11012831 | 2025 | EY | Combating Corneal HSV Infection with Novel Dynasore Analogues | MEDCHEM PARTNERS, LLC | $178,554 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'vaccine' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
Vaccine work in NIH SBIR is overwhelmingly NIAID-driven: 381 of 891 records (43%) sit at NIAID. NCI follows with 206 records, mostly therapeutic cancer vaccines. NIGMS at 83 captures basic mechanism work. The pandemic-era investment in vaccine platforms is still visible in the dataset (the FY2023-FY2025 window includes the trailing edge of COVID-related funding). Median award is $639K. R44 share (465) is dominant. STTR (R41 at 113) is meaningful. Concentration is moderate at 5.2%.
Fit indicators
Watchouts